| Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling EG Bluemn, IM Coleman, JM Lucas, RT Coleman, S Hernandez-Lopez, ... Cancer cell 32 (4), 474-489. e6, 2017 | 687 | 2017 |
| Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer MP Labrecque, IM Coleman, LG Brown, LD True, L Kollath, B Lakely, ... The Journal of clinical investigation 129 (10), 4492-4505, 2019 | 358 | 2019 |
| Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ... Science translational medicine 7 (269), 269ra2-269ra2, 2015 | 279 | 2015 |
| Small cell carcinoma of the prostate R Nadal, M Schweizer, ON Kryvenko, JI Epstein, MA Eisenberger Nature Reviews Urology 11 (4), 213-219, 2014 | 272 | 2014 |
| Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer DN Rodrigues, P Rescigno, D Liu, W Yuan, S Carreira, MB Lambros, ... The Journal of clinical investigation 128 (10), 4441-4453, 2018 | 222 | 2018 |
| Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study BA Teply, H Wang, B Luber, R Sullivan, I Rifkind, A Bruns, A Spitz, ... The Lancet Oncology 19 (1), 76-86, 2018 | 198 | 2018 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 189 | 2021 |
| MSH2 loss in primary prostate cancer LB Guedes, ES Antonarakis, MT Schweizer, N Mirkheshti, F Almutairi, ... Clinical cancer research 23 (22), 6863-6874, 2017 | 160 | 2017 |
| Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations CH Marshall, AO Sokolova, AL McNatty, HH Cheng, MA Eisenberger, ... European urology 76 (4), 452-458, 2019 | 158 | 2019 |
| The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer MT Schweizer, XC Zhou, H Wang, S Bassi, MA Carducci, MA Eisenberger, ... European urology 66 (4), 646-652, 2014 | 153 | 2014 |
| A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer MT Schweizer, K Haugk, JS McKiernan, R Gulati, HH Cheng, JL Maes, ... PloS one 13 (6), e0198389, 2018 | 136 | 2018 |
| Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference K Jensen, EQ Konnick, MT Schweizer, AO Sokolova, P Grivas, HH Cheng, ... JAMA oncology 7 (1), 107-110, 2021 | 125 | 2021 |
| Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy MT Schweizer, XC Zhou, H Wang, T Yang, F Shaukat, AW Partin, ... Annals of Oncology 24 (11), 2881-2886, 2013 | 122 | 2013 |
| Microsatellite instability in prostate cancer by PCR or next-generation sequencing JA Hempelmann, CM Lockwood, EQ Konnick, MT Schweizer, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 120 | 2018 |
| TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer SR Denmeade, H Wang, N Agarwal, DC Smith, MT Schweizer, MN Stein, ... Journal of Clinical Oncology 39 (12), 1371-1382, 2021 | 114 | 2021 |
| Clinical activity of enzalutamide versus docetaxel in men with castration‐resistant prostate cancer progressing after abiraterone DL Suzman, B Luber, MT Schweizer, R Nadal, ES Antonarakis The Prostate 74 (13), 1278-1285, 2014 | 110 | 2014 |
| A phase Ib/IIa study of the pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer RR Aggarwal, MT Schweizer, DM Nanus, AJ Pantuck, EI Heath, ... Clinical Cancer Research 26 (20), 5338-5347, 2020 | 99 | 2020 |
| Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations MT Schweizer, ES Antonarakis, TA Bismar, LB Guedes, HH Cheng, ... JCO precision oncology 3, 1-9, 2019 | 96 | 2019 |
| Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies LS Graham, B Montgomery, HH Cheng, EY Yu, PS Nelson, C Pritchard, ... PLoS One 15 (5), e0233260, 2020 | 94 | 2020 |
| Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage P Chatterjee, MT Schweizer, JM Lucas, I Coleman, MD Nyquist, SB Frank, ... The Journal of clinical investigation 129 (10), 4245-4260, 2019 | 93 | 2019 |
